ACIP Presentation Slides: October 23-24, 2024 Meeting

October 23, 2024

Welcome & Introductions

Introduction

Dr. K Talbot

Dr. M Wharton

Pneumococcal Vaccines

Introduction

Dr. J Loehr

Economic Analysis and public health impact of PCV use for adults aged ≥50 years

Dr. C Stoecker

Summary of economic analyses of PCV use in adults aged ≥50 years

Dr. A Leidner

Summary of WG Interpretation of EtR and policy options on PCV use in adults aged ≥50 years; Clinical considerations for PCV use in adults

Dr. M Kobayashi

Influenza Vaccines

Introduction

Dr. J Loehr

Vaccine Effectiveness Update

Dr. S Ellington

Influenza A/H5 update

Dr. T Shimabukuro

Chikungunya Vaccines

Introduction

Dr. E Asturias

Update on chikungunya and chikungunya vaccines

Dr. S Hills

Virus-like particle chikungunya vaccine

Dr. V Jenkins

Work group interpretation of vaccine data

Dr. S Hills

COVID-19 Vaccines

Introduction

Dr. R Schechter

COVID-19 vaccine uptake and implementation

Dr. G Peacock

COVID-19 epidemiology

Dr. C Taylor

COVID-19 vaccine effectiveness

Dr. R Link-Gelles

Economic analysis of an additional dose of the 2024-2025 COVID-19 vaccine

Dr. L Prosser

EtR

Ms. L Roper

Clinical considerations

Dr. L Panagiotakopoulos

Respiratory Syncytial Virus (RSV) Vaccines - Maternal/Pediatric

Introduction

Dr. H Chu

Safety and efficacy of clesrovimab

Dr. A Sinha

Maternal RSV vaccine safety

Dr. MB DeSilva

Workgroup considerations

Ms. D Moulia

October 24, 2024

Welcome & Introductions

Dr. K Talbot

Dr. M Wharton

Meningococcal Vaccines

Introduction

Dr. J Loehr

Economic analysis of GSK MenABCWY vaccine and comparison of GSK and CDC analyses

Dr. X Dong

GRADE/EtR for GSK MenABCWY vaccine

Dr. S Schillie

Introduction to Bexsero interval and dosing label change; EtR for Bexsero interval and dosing change; Summary of work group considerations regarding Bexsero interval and dosing change

Dr. S Schillie

Respiratory Syncytial Virus (RSV) Vaccines - Adult

Introduction

Dr. A Shaw

Moderna coadministration with high-dose influenza vaccine

TBD (Moderna)

Pfizer immunogenicity in immunocompromised adults, coadministration with COVID-19 and high-dose influenza vaccines

Dr. I Munjal

GSK season 3 efficacy, immunogenicity in immunocompromised adults

Dr. S Gerber

FDA self-controlled case series GBS update

Dr. P Lloyd

Workgroup interpretations

Dr. M Melgar

Immunization Schedules

Introduction to 2025 adult and child/adolescent immunization schedule

Dr. S Cineas

2025 child and adolescent schedule revisions

Dr. N Issa

2025 adult schedule revisions

Dr. P Wodi

Human papillomavirus (HPV) Vaccines

Introduction

Dr. O Brooks

Introduction to policy consideration: reduced number of doses

Dr. L Markowitz

Introduction to policy consideration: wording of the age for routine vaccination

Dr. R Stefanos

Review of the literature on HPV vaccination at ages 9-10 to increase coverage

Dr. S Brewer

Work group - next steps

Dr. C DeSisto

Cytomegalovirus (CMV) Vaccine

Introduction: formation of the CMV vaccine workgroup

Dr. D Jamieson

Mpox Vaccine

Clade 1 Mpox Outbreak in Africa: Situational Update

Dr. A Rao